Lim, Alison E. (2026) The role of local anaesthetic biopsy in the head and neck cancer diagnostic pathways. PhD thesis, University of Glasgow.
Full text available as:|
PDF (edited version, articles under copyright removed)
Download (2MB) |
Abstract
The incidence of head and neck cancer (HNC) is rising in the United Kingdom (UK), leading to growing pressures on HNC services. Cancer Research UK estimates that cancer referrals will rise by 21% in the next 5 years, with 300,000 patients experiencing delays in cancer treatment[8,9]. HNC pathways are saturated with referrals, resulting in prolonged waits to diagnose HNC and subsequent delays in initiating cancer treatment. This thesis explores existing problems in the diagnostic pathway for HNC in the UK and offers novel solutions, focusing on improving pathway efficiency through the use of local anaesthetic (LA) biopsy.
To initiate referral into the HNC pathway, a patient must recognise red flag symptoms and present to a healthcare professional. Patients with HNC often present with advanced stage disease, which contributes to poor morbidity and mortality outcomes[10] . Article 1 represents the first investigation into the patient-related factors that contribute to the late presentation seen in HNC. Crucially, it was identified that cancer patients take longer to present with symptoms in comparison to patients with benign disease. Presentation delay was most often a consequence of the patient not recognising concerning symptoms. This highlights the urgent need to educate patients about red flag symptoms, through public health campaigning and targeting high risk groups by health promotion during routine healthcare interactions.
The National Health Service (NHS) recommends 95% of patients should have their cancer treatment started within 62 days of referral[11]. Article 2 offers original insight into the impact of LA biopsy on pathway times in the UK. In an observational cohort, LA biopsy was associated with significantly shorter times to biopsy and multidisciplinary team (MDT) discussion in comparison to general anaesthetic (GA) biopsy. Integration of LA biopsy into outpatient services may offer a solution to extended diagnostic waiting times, with the potential to lead to earlier and more effective treatment.
Despite the exciting potential of LA biopsy, its routine use in the UK is limited. Although there have been anecdotal reports, real-world clinical utilisation of LA biopsy has not previously been quantified in the UK. This knowledge gap is addressed by Article 3, a UK-wide survey regarding utilisation of LA biopsy in current clinical practice. Few clinicians employ LA biopsy, with less than half (48%) reporting use of endoscopic and oral LA biopsy. Reasons for not using LA biopsy included concerns about clinic over-running, complications, missing a synchronous primary cancer (SPC) and poor patient tolerance. Regardless of the potential benefits of LA biopsy, it seems that at the individual clinician-level there are several barriers preventing its adoption into routine practice in the UK.
Given that many of the concerns raised in Article 3 lack a strong basis in the literature, Articles 4-6 seek to strengthen the evidence-base for potential benefits of LA biopsy and address the reservations. Article 4 is the first systematic literature review to investigate complications associated with HNC LA biopsy. Rates of minor and serious complications requiring intervention were both rare (<0.01%), comparable to GA biopsy rates. Article 5 addresses a gap in the literature by providing insight to patients' perspective and satisfaction after experiencing LA biopsy. Patients on LA and GA pathways were asked to complete questionnaires about their experience. A questionnaire specific to LA biopsy in HNC was not previously described, so the authors adapted from a validated gastrointestinal questionnaire to address this clinical question. There was no significant difference in patient-reported pain or discomfort scores and overall satisfaction was high. Article 6 investigated the rates of SPC in a contemporary HNC population and the methods of SPC diagnosis. The rate of SPC was lower than previous reports (2.3%). With the rise of human papilloma virus (HPV)-related HNC, the incidence of SPC has likely decreased due to the reduced effect of 'field cancerisation' seen in smoking-related cancers[12]. The authors developed a new concept of 'comprehensive outpatient assessment', comprising of clinical examination with flexible nasoendoscopy (FNE) and cross-sectional imaging. It was hypothesised and proven that 'comprehensive outpatient assessment' is effective in identifying SPC, without the requirement of GA panendoscopy. These results provide evidence-based reassurance to clinicians that a GA can be avoided, if not otherwise indicated. Clinicians must combine an understanding of the shifting aetiology of HNC and the efficacy of contemporary high-resolution endoscopic and imaging technology, to rationalise investigations for HNC.
Article 7 is a collaborative research study that gathered real-world data on the clinical factors influencing HNC pathway times, at a national, multi-centre level. Routinely-collected waiting times data is published annually, but this study employed novel methodology to gain granular clinical data. There was poorer target compliance (34.6%) with targets than expected from national reports. Analysis of investigation pathways demonstrated that time to imaging, in particular Positron Emission Tomography-Computed Tomography (PET-CT), had prolonged delays (median 49 days). Clinical factors that improved compliance with pathway targets included referral through urgent cancer pathway, early tumour stage, avoidance of a GA biopsy and surgical treatment- highlighting areas specific to HNC that may guide future improvements to the service. Compliance with HNC targets did not have any significant impact on 2-year survival outcomes, demonstrating that assessment of service performance through generic targets may not reflect a true clinical benefit. Scrutiny of cancer-specific datamay help determine factors that can have a material, positive impact on patient morbidity and mortality.
This thesis explores deficiencies in the diagnostic pathway for HNC and challenges the traditional practice of investigating patients universally with panendoscopy. It provides novel evidence of the benefits of LA biopsy on cancer waiting times and demonstrates patient satisfaction and safety. LA biopsy has been incorporated in recent HNC guidelines[11] and in appropriate patients, should be offered as a first-line method of biopsy. Investment in outpatient services will be necessary to accommodate for increasing HNC referrals, and should include provision of equipment and staff for LA biopsy. Clinical data has demonstrated that compliance with pathway targets may not reflect clinical benefit, and a greater understanding of cancer-specific factors is needed to improve the service in a meaningful way to improve patient outcomes.
| Item Type: | Thesis (PhD) |
|---|---|
| Qualification Level: | Doctoral |
| Additional Information: | Thesis contains 7 articles of published work (PhD by publication) which are not published on an open access license. Thesis submitted without articles. |
| Subjects: | R Medicine > RB Pathology R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
| Colleges/Schools: | College of Medical Veterinary and Life Sciences |
| Supervisor's Name: | Walters, Professor Matthew and Montgomery, Ms. Jenny |
| Date of Award: | 2026 |
| Depositing User: | Theses Team |
| Unique ID: | glathesis:2026-86294 |
| Copyright: | Copyright of this thesis is held by the author. |
| Date Deposited: | 05 Nov 2026 11:30 |
| Last Modified: | 05 Nov 2026 11:46 |
| Thesis DOI: | 10.5525/gla.thesis.86294 |
| URI: | https://theses.gla.ac.uk/id/eprint/86294 |
| Related URLs: |
Actions (login required)
![]() |
View Item |
Downloads
Downloads per month over past year

Tools
Tools